(IN BRIEF) Boehringer Ingelheim has received approval from Japan’s Ministry of Health, Labour and Welfare for JASCAYD® (nerandomilast) to treat adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The oral PDE4B inhibitor is the first therapy of its kind … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology
Tagged antifibrotic treatment, Arata Azuma, Boehringer Ingelheim, clinical trials, FIBRONEER, fibrosis treatment, forced vital capacity, idiopathic pulmonary fibrosis, immunomodulatory therapy, IPF, Japan Ministry of Health Labour and Welfare, JASCAYD, lung disease, lung function decline, MHLW, nerandomilast, PDE4B inhibitor, pharmaceutical industry, PPF, progressive pulmonary fibrosis, pulmonary fibrosis, rare diseases, respiratory health, respiratory medicine, Shashank Deshpande
(IN BRIEF) Evotec, Yonsei University, and Zymedi have been awarded a US$ 4.5 million grant from the Korea Institute of Advanced Technology (KIAT) to develop first-in-class biologic therapies for lung diseases, specifically asthma and idiopathic pulmonary fibrosis (IPF). The project … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged anti-fibrotic antibodies, anti-inflammatory antibodies, antibody development, asthma, biologic therapies, disease-causing enzymes, Evotec, fibrosis, idiopathic pulmonary fibrosis, IPF, KIAT, Korea Institute of Advanced Technology, lung diseases, novel mechanism-of-action, novel therapies, partnership, preclinical R&D, Sunghoon Kim, therapeutic antibodies, Thomas Hanke, tRNA synthetases, unmet medical needs, US$ 4.5 million grant, Yonsei University, Zymedi
AstraZeneca / BenevolentAI artificial intelligence collaboration will accelerate drug discovery Potential new drugs discovery in the area of chronic kidney disease and idiopathic pulmonary fibrosis (PRESS RELEASE) CAMBRIDGE / LONDON, 30-Apr-2019 — /EuropaWire/ — New partnership, announced today, by AstraZeneca … Read the full press release
Posted in Artificial Intelligence (AI), Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AI, AI discovery platform, artificial-intelligence, AstraZeneca, Benevolent Platform, BenevolentAI, biomedical knowledge graph, chemistry, Christina Malmberg Hägerstrand, Chronic kidney disease, CKD, clinical data, disease biology, genomics, Gonzalo Viña, idiopathic pulmonary fibrosis, IPF, Jennifer Hursit, Joanna Shields, Machine Learning, Matt Kent, Mene Pangalos, Michele Meixell, pathophysiology of disease, Rebecca Einhorn, Rob Skelding
61% of IPF patients are worried or extremely worried about experiencing an acute IPF exacerbation1 Survey underlines the importance of appropriate support and coping mechanisms for patients living with IPF1 Healthcare teams emphasise the need of a strong support network … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Society
Tagged Boehringer Ingelheim, Dr. Marlies Wijsenbeek, idiopathic pulmonary fibrosis, IPF, survey
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?